NICE extends recommendations for Sovaldi, Olysio

The U.K.'s NICE extended earlier draft recommendations for Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) to include additional HCV genotypes.

The committee's final draft guidance now recommends Sovaldi in combination with peginterferon alfa (IFN) and ribavirin to treat HCV genotype 4, 5 and 6 infections in adults with cirrhosis. The committee said the Sovaldi combination could be cost-effective for patients with those three HCV genotypes and cirrhosis if their incremental cost-effectiveness ratios (ICERs) were L20,000-L30,000 ($30,228-$45,342) per quality-adjusted life year (QALY) gained. ...